Metformin as an adjunct anti-COVID-19 agent

Due to the paucity of safe and effective COVID-19 medicines, there is a pressing need for treatment options given the current pandemic. For clinical testing, established medications should be chosen over new ones because of their low cost, clinical management, and safety profiling. Although the three most popular vaccines, Modera, Pfizer NSE, and Oxford-AstraZeneca are currently more effective against SARS-CoV-2 infection, their acquisition and storage are quite expensive for developing and impoverished nations that desperately need them. However, inexpensive vaccination options are not very effective. In this scenario, there is a need for affordable medication candidates that are already available and can be added to less expensive vaccinations to boost their effectiveness. Metformin, a medication used to treat diabetes, may improve the effectiveness of vaccinations. New research has shown that memory T cells adapt their energy source to withstand viral or other infections. Rather than burning glucose as do other cells, they begin to burn fat. Certain engineered mice strains were unable to produce memory T cells because they lacked the capacity to alter their fuel sources. However, when metformin was administered to these specially bred mice, the medicine helped the animals produce memory T cells [28]. Therefore, this commonly used medication may improve immunization campaigns. Metformin is being viewed as an adjuvant therapy to anti-tuberculosis medication since it decreases the growth of Mycobacterium tuberculosis intracellularly [29]. It is possible that it could also be potentially effective for anti-COVID-19 therapy.

Metformin and high blood glucose crosstalk

T2D is characterized by a loss of glycemic control often due to insulin resistance (IR) in metabolic tissues such as adipose and muscle [30]. In a recent study, Ye et al. [31] claimed that elevated circulatory glucose elevates Kaposi sarcoma herpes virus (KSHV) lytic gene expression mediated by hydrogen peroxide and viral replication in various cell types and that induction of the KSHV lytic gene expression by high glucose is mediated by H₂O₂. In 2020, Cuong and Thoa [32] demonstrated that high glucose-fed adult zebrafish increased their mRNA levels for inflammatory cytokines and demonstrated elevated endoplasmic reticulum (ER) stress after being challenged with KSHV. High glucose also induces replication of the HCV in the host cells [33]. Hyperglycemia-induced enzymatic glycosylation can affect the action of numerous proteins [34]. Glycosylation of ACE2 promotes virus linkage to its cellular receptor and affects the severity of the disease [35]. ACE2 activity in the lung did not increase in the non-obese diabetic (NOD) mice model, although ACE2 protein levels rose. This is in accordance with an increase in ACE2’s glycosylated form [36]. Increase of SARS-CoV-2 viral binding sites may also be caused by potentially elevated and aberrant ACE2 glycosylation in respiratory system tissues including lungs, nasal airways, nasopharynx, and tongue due to uncontrolled hyperglycemia thereby enhancing the risk of COVID-19 infection and severity of the disease [37]. Metformin, a conventional drug, responds against increased glucose and helps restore the glucose equilibrium like most other anti-diabetic drugs to maintain a glycemic state. All the above reports indicate a possible role for metformin against COVID-19. A recent study highlights the role of COVID-19 infections in promoting type 1 diabetes among children [38–40].

Metformin and IR crosstalk

IR is a multi-component dependent physiological state where increasing quantities of insulin are required for maintaining glycemic homeostasis and sufficient glucose consumption in insulin target tissues. IR occurs when cells of muscle, fat, and liver tissue do not respond adequately to insulin and cannot utilize blood glucose for energy metabolism. To make up for the deficit, the pancreas produces more insulin. Over time, the patient’s blood sugar levels rise [41]. Pro-inflammatory cytokines from T helper-1 cells are known to promote IR in muscle and adipose tissue [42]. It has long been recognized that infection, thermal injury, and a variety of traumatic conditions markedly increase IR [43]. HCV infection poses the danger of developing IR. HCV-induced IR is due to the core protein of HCV that induces proteasomal degradation of insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) and blocks intracellular insulin signaling. It is commonly known that people with diabetes have a higher risk of influenza-associated morbidity and mortality [44]. This risk is linked to the onset of ketoacidosis, a metabolic condition, and a higher risk of secondary bacterial pneumonia compared to non-diabetics. HIV-positive individuals frequently experience IR, especially those receiving protease inhibitor therapy. When using anti-retroviral (ARV) therapy for HIV infection, the prevalence of hyperglycemia and DM is much greater than in the general population [45]. Working with a mouse model of diet-induced obesity, Hadjadj and co-workers [46] demonstrated that IR causes a substantial ACE2 over-expression in lungs. This negatively correlates with the expression of sterol response element-binding proteins 1 and 2 (SREBP1 and 2). The anti-hyperglycemic effect of metformin is a result of the drug’s action on the reduction of IR in liver, muscle, and adipose tissue. It is likely that the interaction among the effects across three different tissues brings about the overall beneficial effect of metformin [47] and suggests a potential role in the battle against COVID-19.

Metformin-autophagy-mTOR complex-1 crosstalk

When intracellular components like protein aggregates, damaged organelles, and pathogens are engulfed into double-membrane structures called autophagosomes, they are degraded by an evolutionarily conserved process known as macroautophagy or autophagy. These autophagosomes then fuse with lysosomes to form autolysosomes [48]. A significant amount of interest has been paid in the last fifteen years to the role autophagy plays in coronavirus infection, largely because of the 2002–2003 SARS outbreak. It has been shown that either autophagy related gene 5 (ATG5) or ATG7, two essential autophagy proteins involved in the regulation of autophagosome synthesis, are needed to prevent viral replication in cells infected with mouse hepatitis virus (MHV) or SARS-CoVs [49]. The viral replication rate was not inhibited by cells that had either the ATG5 or ATG7 deletion. Recently in 2021, Gassen et al. [50] reported that SARS-CoV-2 infection limits autophagy by interfering with multiple metabolic pathways. In addition, compound-driven intervention aimed at autophagy induction to reduce SARS-CoV-2 propagation in vitro is via activation of the mammalian target of rapamycin (mTOR) pathway. Rapamycin is the most potent inducer of autophagy. It operates via down-regulation of the mTOR complex-1 and researchers propose low-dose rapamycin is required for protecting the elderly from COVID-19 [51]. In addition to regulating the antibody response for cross-protective immunity against infectious influenza viruses, mTOR signaling is a key player in the pathophysiology of influenza. Metformin can also indirectly influence the mTOR pathway in addition to rapamycin [52]. Gordon and co-workers [53] predicted that metformin could be used as an anti-COVID drug. Metformin inhibits the mTOR pathway by activating AMPK through liver kinase B1 (LKB1). Additionally, it phosphorylates IRS-1, which inhibits the mTOR signaling cascade and indirectly attenuates AKT activation [54]. Singhal et al. [29] reported that metformin inhibits the intracellular growth of M. tb by inducing autophagy selectively via enhanced mitochondrial reactive oxygen species (ROS) production. Metformin, therefore, could be a game-changer in the management of COVID-19 infection.

Metformin modulates the severity of virus infections

HIV attacks CD4⁺ immune cells [55]. These lymphocytes course through the body, detecting any infections as well as anomalies in other cells. When HIV targets and infects these cells, it compromises the body’s ability to combat other diseases. AIDS is the most advanced stage of HIV infection. HIV patients have an increased risk of diabetes, cardiovascular disease, cancer, and tuberculosis [56]. Metformin treatment was found to ease arterial blockage and slow the advancement of coronary artery calcification in HIV-positive patients, without affecting CD4 counts or viral loads [57]. It is still uncertain what mechanism underlies this phenomenon. Liver failure, malignancy, and scarring are all possible outcomes of hepatitis B infection. If treatment is not given, it is lethal [58]. Hepatitis B surface antigen (HBsAg) levels in culture supernatants and HepG2 cell lysates decreased following metformin treatment, according to one study [59]. Hepatitis B e antigen (HBeAg) expression, HBV replication, and HBsAg production were all dramatically reduced by metformin. These findings imply that metformin may lessen the long-term consequences of HBV, even though the exact mechanism needs to be explored further. Hepatitis C is another viral infection that causes liver inflammation, sometimes leading to serious liver damage [60]. The HCV spreads through contaminated blood. Many HCV-positive individuals were unable to take the weekly injections and oral drugs required for hepatitis C treatment due to other medical conditions or intolerable side effects [61]. Research on the impact of metformin on patients with chronic hepatitis C has yielded inconsistent findings. In a study involving the treatment of chronic hepatitis C, Sharifi et al. [61] demonstrated improvement in sustained viral response (SVR) when metformin was added to the antiviral therapy [pegylated interferon (IFN) and ribavirin]. It remains to be seen if metformin would inhibit the SARS-CoV-2 virus by stimulating these pathways.

Metformin and ACE2 receptor crosstalk

The mechanism by which SARS-CoV-2 enters host cells through ACE2 receptors is now well established [62]. A catalytic enzyme called ACE2 is expressed on the plasma membrane of cells found in the kidney, intestines, heart, lungs, and arteries [63]. By catalyzing the conversion of angiotensin (Ang) II, a vasoconstrictor peptide, into Ang 1–7, a vasodilator, ACE2 reduces blood pressure [64]. Due to the higher expression of the ACE2 receptor gene, Asian men have been shown to be more susceptible to SARS-CoV-2 infection than women and people of other races [65]. But compared to adults, children are less vulnerable to COVID-19. Lower ACE2 expression is the cause of this [66, 67]. According to Wrapp and co-workers [68], the S protein from SARS-CoV-2 has a 10–20-fold higher affinity for ACE2 than the S protein from SARS-CoV.

The higher infectivity that results from this, according to the authors’ theory, may help to explain why the two epidemics’ evolutionary paths diverge. In addition to COVID-19, ACE2 guards against sepsis, acid aspiration, SARS, and fatal avian influenza A H5N1 virus infection, which can all cause severe acute lung injury [69]. DM, cancer, and cardiovascular disorders are among the conditions where the energy sensor AMPK exhibits abnormal expression. AMPK signaling induction increases glucose homeostasis in diabetes, which is crucial for reducing hyperglycemia. AMPK can help with liver disorders, nephropathy, neuropathy, and reproductive changes brought on by DM. To achieve these protective effects, AMPK signaling engages in the PI3K/Akt pathway and has interactions with transcription factors, including peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and NF-κB [70]. Based on the literature, it is speculated that AMPK could regulate the expression of ACE2. But this effect may be tissue- or cell-type-dependent, and it can vary between tissues. Utilizing cell culture models, Liu et al. [71] showed that AMPK increased the expression of ACE2 by hampering its ubiquitination and proteasomal degradation. In addition, they also observed increased receptor stability due to phosphorylation at Ser680 [71]. It is conceivable, that this addition of a phosphate may cause conformational and functional changes in the ACE2 receptor that can inhibit the binding of S protein to the ACE2 receptor.

In a separate investigation, oral Ang (1–7) and resveratrol feeding to mice on a high-fat diet (HFD) resulted in enhanced AMPK activity and decreased expression of ACE in white adipose tissue [72]. AMPK may control the expression of ACE and elevating AMPK phosphorylation can inhibit the expression of ACE2. It is known that metformin causes cells’ AMPK to become active [73]. The investigation of Gilbert et al. [74] revealed a substantial correlation between urine ACE2 and metabolites such as elevated triglycerides, cholesterol, and blood sugar. Enzyme activity and protein level expression of urinary ACE2 were found to be attenuated by the administration of insulin, rosiglitazone, and metformin, agents known to control hyperglycemia [74]. Therefore, metformin by inducing post-translational modifications in the ACE2 receptor via activation of AMPK-signaling may prevent the cellular entry of SARS-CoV-2 and may prevent the development of cardinal signs of COVID-19, which is exemplified in Figure 2.

Display full size

Figure 2. 

Metformin could affect the COVID-19 severity via post-translational modification of the ACE2 receptor via activation of AMPK-signaling pathway. COVID-19: coronavirus disease-2019; ROS: reactive oxygen species; MAS: Mas receptor; ACE2: angiotensin-converting enzyme 2. Created with BioRender.com

Metformin and anti-inflammatory crosstalk

SARS-CoV-2 also inflicts damage to organs like heart, liver, kidneys, as well as to the immune system along with pneumonia-like symptoms. Severely afflicted patients eventually die due to multiple organ failure, shock, acute respiratory distress syndrome (ARDS), heart failure, arrhythmias, and renal failure [75]. Multi-organ failures are usually brought upon by “cytokine storm”, overwhelming the host immune response to SARS-CoV-2 infection [76, 77]. Recently, Theobald et al. [78] showed that SARS-CoV-2 S protein drives inflammasome activation and interleukin-1 beta (IL-1β) secretion. Neutrophil extracellular traps (NETs) are networks of extracellular fibers, consisting of DNA from neutrophils, which bind pathogens [79]. According to recent research, serum from COVID-19 patients has greater levels of NETs, including citrullinated histone H3 (Cit-H3), myeloperoxidase (MPO), and cell-free DNA. These have been linked to inflammatory markers [80]. In patients with diabetes, metformin has been linked to a reduction in the neutrophil-lymphocyte ratio and a decrease in the neutrophil count in PCOS [81]. Metformin also ameliorated NETosis in patients with diabetes [82]. Several preclinical and clinical studies suggested that metformin improves chronic inflammation by improving metabolic parameters such as hyperglycemia, IR, atherogenic dyslipidemia along with direct anti-inflammatory action [83]. Anti-inflammatory effect of metformin is induced by the inhibition of NF-κB via AMPK-dependent and independent pathways [84]. In another study, metformin, and the inhibitor of kappa B kinase beta (IKKβ) inhibitor BI605906 both inhibited TNF-α dependent IκB degradation and expression of pro-inflammatory mediators’ IL-6, IL-1β, and CXCL1/2 in primary hepatocytes [81]. Metformin reduces IFNγ levels and increases forkhead box P3 (FOXP3) mRNA expression in mice models of systemic lupus erythematosus (SLE) [85]. Jing et al. [86] showed metformin altered macrophage polarization by reducing TNF-α expression from macrophages. Another study by Duan et al. [87] demonstrated that metformin suppresses T cell proliferation and inhibits the differentiation of Th1 and Th17 cells while promoting the development of Tregs in vitro in a dose-dependent manner. Recently, Bharath and co-workers [88] reported that metformin ameliorated Th17-based inflammation by increasing autophagy and improving mitochondrial bioenergetics. Metformin not only reduces inflammatory response but also improves the phagocytosis by immune cells [89] which is a component of the innate immune system. Bramante et al. [90] showed that metformin may lower the risk of COVID-19 fatality in women. Metformin reduced the inflammation marker C-reactive protein (CRP) twice as much in women than in men and significantly decreased levels of TNF-α, an inflammatory cytokine that appears to make the effects of COVID-19 more severe. Since metformin inhibits pro-inflammatory cytokines production, it could be a direct modulator of the innate as well as adaptive immune response, thus preventing viral replication and pathogenesis.

Metformin-aging-COVID-19 crosstalk

Human aging can alter the body in a variety of ways, which can subsequently impact the immune system. For example, aging can cause the body to react more violently to antigens that have a reduced ability to thwart infections. Individuals over 60 years of age have a 4.5% mortality rate, while individuals under 60 have a 1.4% mortality rate. As a result, therapeutic approaches may be less effective in older patients. To lower the death rate, managing older COVID-19-infected individuals has thus become a significant concern [91]. A typical medication used to treat T2D in people is metformin. Moreover, metformin contains anti-inflammatory properties, which may help explain why it can delay the aging process. Reducing inflammation can enhance health and prolong life because persistent inflammation is a sign of aging and age-related disorders. Martin-Montalvo and co-workers [92] have reported that metformin (0.1% w/w in food) given to male mice over an extended period beginning in middle age increases their lifespan and quality of life, while a higher dose (1% w/w) was harmful. Without lowering caloric consumption, metformin treatment mimics some of the advantages of calorie restriction, including enhanced insulin sensitivity, decreased levels of low-density lipoprotein and cholesterol, and improved physical performance [92]. There has been speculation that the low number of deaths in India can be attributed to two factors: the virus’s less virulent strain and the country’s comparatively youthful population when compared to western societies which have a higher percentage of elderly individuals. The vulnerability of Indians to COVID-19 may be reduced by several factors pertaining to the type of pathogen, host, and environment conditions. These include genetic polymorphisms of ACE2 receptors, host factors such as innate immunity, genetic diversity in immune responses, epigenetic factors, and the universal BCG vaccination. Environmental factors such as high temperature and humidity can also affect the viability and transmissibility of the strain. Finally, some ongoing mutations that alter the virulence of the circulating SARS-CoV-2 strains are also included [93].

Metformin and type 1 IFN crosstalk

The well-researched cytokines type 1 IFNs have antiviral and immune-modulating properties [94]. A secreted substance known as “interferon” was discovered by Isaacs et al. [95] in 1957, and it was shown to be able to make influenza virus-infected chick cells resistant to infection. There are several IFNα, IFNβ, ε, κ, and ω subtypes in the type 1 IFN family, in addition to the δ and τ subtypes that are specific to sheep and pigs, respectively. By attaching to the type 1 IFNα/β receptor (IFNAR), which is found in a range of cell types, these cytokines trigger antiviral responses [96]. Despite variations in their pathophysiology, proteome, and epidemiology, MERS-CoV, SARS-CoV, and SARS-CoV-2 share similar features [96]. Intriguingly SARS-CoV-2 is relatively more sensitive to type 1 IFN than SARS-CoV suggesting the modulation of type 1 IFN to reduce SARS-CoV-2 infection [97]. The combination of type 1 IFN agonists with lopinavir/ritonavir, ribavirin, or remdesivir could improve its efficacy [98]. Unfortunately, SARS-CoV-2 infection causes impairment in type 1 IFN activity in patients [46]. Recently, Blanco-Melo et al. [99] showed that SARS-CoV-2 infection induces low IFN-I and IFN-III levels with a moderate IFN-stimulated gene response. In 2010, Tsai and Chung [100] showed metformin activates type 1 IFN signaling and inhibits the replication of herpes virus via activation of AMPK. It may be possible to induce the production of type 1 IFN and metformin could be a candidate small molecule for COVID-19 therapy.

Metformin-mitochondria-cell death crosstalk

Mitochondria are membrane-bound cell organelles that provide most of the chemical energy required for the cell’s metabolic activities. Adenosine triphosphate (ATP) stores the chemical energy generated by oxidative phosphorylation that takes place in mitochondria. In addition to generating most of the energy required for cellular processes, mitochondria also play a key role in the control of cellular homeostasis, cell metabolism, innate immunity, cell death, and epigenetics [101]. Approximately one thousand distinct proteins, each with a unique function, are found within mitochondria. These proteins rely on the exchange of ions and metabolites between the mitochondria and the cytoplasm. Consequently, it is necessary for metabolites to pass through both the inner and outer mitochondrial membrane (IMM and OMM). Metabolites can be transferred across the OMM by the voltage-dependent anion channel 1 (VDAC1). The IMM is furnished with numerous transporters or carrier proteins, each of which oversees moving a particular metabolite across the IMM [102, 103]. Thompson and co-workers [104] demonstrated a specific T cell population seen in COVID-19 patients that is marked by strong VDAC1 and H3K27me3 epigenetic marker overexpression. According to Loubiere et al. [105], metformin has also been shown to enhance VDAC1 expression levels in LNCaP cells. It has also been shown to do the same in rats treated with metformin that resemble those with PCOS [105]. Zhang et al. [106] showed that in PCOS-like rats treated with metformin, there was an increase in VDAC expression and a decrease in superoxide dismutase 1 (SOD1) in comparison to control rats. Furthermore, it was observed that metformin modulates pathological conditions in which VDAC1 is overexpressed. VDAC1 overexpression induces mitochondrial dysfunction, which leads to cell death [107]. Therefore, metformin could play a decisive role in COVID-19 via modulating the VDAC1 expression and cell death of SARS-CoV-2-infected cells.

Metformin partially inhibits complex 1 of the electron transport chain in the mitochondria [108]. This results in an irregular electron-to-oxygen flow and the accumulation of ROS in the mitochondrial matrix. ROS are thought to play a role in the etiology of several illnesses, such as inflammation and cancer. Additionally, ROS are required for the differentiation, secretion, growth, and killing of tumor cells. Nonetheless, apoptosis and senescence of tumor cells might be brought on by elevated ROS levels. Additionally, ROS cause the membrane potential (∆ψm) to collapse, which sets off a sequence of events related to mitochondria, such as apoptosis and necroptosis [109–111]. Metformin also induces the killing of cancer cells via targeting the extracellular signal-regulated kinases (ERK) pathway [112]. This suggests that metformin could potentiate the killing of SARS-CoV-2 infected cells and help in the clearance of the virus.

Metformin and oxidative stress axis

A redox imbalance of oxidative stress (OS) may be connected to cytokine generation, inflammation, cell death, and other pathophysiological processes associated with respiratory virus infections. It is commonly known that excessive formation of ROS and suppression of antioxidant mechanisms are essential for the proliferation of viruses [113]. Increased ROS and Ca⁺⁺ disruptions brought on by unfolded protein response (UPR), which is mediated by ER stress, are linked to viral infections, including SARS-CoV [52]. Viral infections, bacterial toxins, and air pollutants can cause high quantities of ROS to be generated in the lung airways. At the site of viral infection, excessive ROS production causes the recruitment of inflammatory cells [114]. Patients with COVID-19 infection have been shown to have significantly elevated blood levels of cytokines (cytokine storm) and chemokines due to increased immune cell recruitment [31]. The cytokine storm contributes to the catastrophic outcomes of COVID-19 patients by causing a pro-inflammatory milieu that is highly correlated with severe tissue damage [115]. The non-structured protein 3CLpro, a viral protease, of SARS-CoV was shown by Lin and colleagues [116] to be involved in cell death and to significantly boost ROS generation in HL-CZ cells. Chen et al. [117] showed that K⁺ influx and ROS overproduction are adequate triggers for the activation of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP-3) inflammasome caused by SARS-CoV’s protein 3a. In cerebral ischemia, metformin pretreatment stimulates Nrf2 antioxidant pathways and suppresses inflammatory responses by inducing the AMPK pathway [118]. A study by Prasad and co-workers [119] revealed that metformin activates the Nrf2 pathway, which significantly diminishes the toxicity of smoking cigarettes at the cerebrovascular level. Nrf2 is a basic leucine zipper (bZIP) protein that controls antioxidant protein production to prevent oxidative damage brought on by inflammation and injury [120]. McCord et al. [121] showed that Nrf2 activator PB125 down-regulates ACE2 and TMPRSS2 mRNA expression in human liver-derived HepG2 cells and controls the OS response. All these reports indicate that metformin could be a potential drug candidate for COVID-19 treatment.

Metformin and gut microflora crosstalk

The human gut microbiota harbors ~10¹⁴ microorganisms (bacteria, archaea, viruses, and fungi) [122]. Most bacteria in gut belong to: Actinobacteria, Firmicutes, Proteobacteria, and Bacteroidetes phyla [123]. The major families are: Bacteroidaceae, Prevotellaceae, Rikenellaceae, Lachnospiraceae, and Ruminococcaceae [124]. Gut microbiota influence and regulate energy metabolism and inflammation. Fluctuations in microbiota cause obesity, escorted by low-grade inflammation, and pose the risk of gut-associated and other diseases like type 2 DM [125]. Recently Zuo et al. [126] reported that microbiota changes during the time of hospitalization, for Coprobacillus, Clostridium ramosum, and C. hathewayi (pro-inflammatory bacteria) correlated with COVID-19 severity. However, an inverse correlation was found among the abundance of Bifidobacterium and Faecalibacterium prausnitzii (anti-inflammatory bacteria) and disease severity. Imaoka et al. [127] showed that probiotic Bifidobacterium strains in fermented milk enhance IL-10 production in peripheral blood mononuclear cell (PBMC) and inhibit IL-8 secretion in intestinal epithelial cells, suggesting that Bifidobacterium strains have anti-inflammatory effects against ulcerative colitis. Its metabolic effects are also believed to be caused by altering the gut flora in response to metformin. Most investigations have focused on, how metformin boosts the number of microbiota members, particularly Escherichia coli, B. bifidum, Butyrivibrio, Megasphaera, subspecies of Prevotella, Lactobacillus, and Akkermansia muciniphila [128, 129]. Utilizing an in vitro culture model, it has been observed that metformin also encourages the growth of A. muciniphila and B. adolescentis [130]. Thus, by reducing the pro-inflammatory condition-provoking bacteria in the gut, metformin could be a potential weapon in the battle against COVID-19 (Figure 3).

Display full size

Figure 3. 

Metformin could rewire the dysbiosis of the gut microflora affected by type 2 diabetic condition. This rewiring i.e., increases in Firmicutes and lactobacilli populations in gut microflora decreases coronavirus disease (COVID) severity and cellular inflammation and decreases COVID-19 severity. Created with BioRender.com